<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322099</url>
  </required_header>
  <id_info>
    <org_study_id>APART_2014</org_study_id>
    <nct_id>NCT02322099</nct_id>
  </id_info>
  <brief_title>Alendronate for Prevention of AntiRetroviral Therapy-associated Bone Loss</brief_title>
  <acronym>APART</acronym>
  <official_title>A Multi-centre, Prospective, Randomised Trial of Short Course Alendronate Therapy or Placebo Combined With Vitamin D and Calcium to Prevent Loss of Bone Mineral Density in Antiretroviral-na誰ve, HIV-1 Infected Subjects Initiating Antiretroviral Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University College Dublin</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Health Research Board, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Royal College of Surgeons, Ireland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mater Misericordiae University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beaumont Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rush University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University College Dublin</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Antiretroviral therapy (ART) initiation is associated with a significant loss of bone mineral
      density (BMD), characterised by increases in bone turnover, which is largely limited to the
      first 48 weeks of therapy. Bisphosphonates, such as alendronate, decrease bone turnover and
      can limit loss of bone mineral density.

      This study aims to determine if a short course of treatment with the oral bisphosphonate
      alendronate can limit loss of bone mineral density associated with initiation of ART in HIV-1
      infected, antiretroviral naive, adult subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Multi-centre, prospective, randomised, double-blind, placebo-controlled trial over 50 weeks.
      The aims of this study include:

        1. To determine if short-course treatment with alendronate versus placebo combined with
           calcium and vitamin D, initiated 2 weeks prior to start of ART and can prevent loss of
           BMD over 48 weeks of follow-up post ART initiation.

        2. To explore the effect of alendronate on bone turnover in the setting of ART initiation.

        3. To determine which factors, such as choice of ART, impacts the protective effect of
           alendronate in preventing BMD loss.

        4. To determine the relationship between changes in bone turnover markers, vitamin D,
           parathyroid hormone and calcium levels.

        5. To explore the pathogenesis of BMD loss with initiation of ART by investigating
           relationships between changes in immune function (T-cells and B-cells subsets), bone
           turnover and BMD.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of changes in bone mineral density</measure>
    <time_frame>50 weeks</time_frame>
    <description>Between-group differences in percentage change in total hip, lumbar spine, femoral neck BMD and body composition to week 50 among subjects who received at least one dose of the study medication</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of changes in bone turnover markers</measure>
    <time_frame>50 weeks</time_frame>
    <description>Between-group differences in percentage change in bone turnover markers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of ART choice on alendronate protective effect</measure>
    <time_frame>50 weeks</time_frame>
    <description>Impact of choice of ART on changes in BMD and bone turnover markers</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Pathogenesis of BMD loss with initiation of ART</measure>
    <time_frame>50 weeks</time_frame>
    <description>Relationship between changes in T-cell and B-cell subsets, bone turnover and BMD with ART initiation</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bone Demineralization</condition>
  <arm_group>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alendronate 70 mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada速</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to alendronate 70mg plus calcium/vitamin D (1250 mg/400iu) plus Truvada速</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alendronate</intervention_name>
    <description>alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation</description>
    <arm_group_label>Alendronate</arm_group_label>
    <other_name>Fosamax</other_name>
    <other_name>Romax</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>calcium carbonate and colecalciferol</intervention_name>
    <description>Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation</description>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Calcichew D3 forte</other_name>
    <other_name>Ideos</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir disoproxil</intervention_name>
    <description>Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks</description>
    <arm_group_label>Alendronate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Truvada</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male&gt;30 years old or female&gt;35 years old

          -  HIV-1 antibody positive

          -  antiretroviral therapy na誰ve

          -  be presumed to have achieved peak bone mass

          -  be eligible for initiation of antiretroviral therapy in the opinion of the
             investigator

          -  be able to provide written, informed consent

        Exclusion Criteria:

          -  subjects unable to comply with the study protocol or unable to stand/sit upright for
             at least 30 minutes

          -  history of osteoporosis

          -  history of fragility fracture or previous femoral fracture

          -  chronic renal failure

          -  hypocalcemia or hypercalcemia at screening

          -  history of Paget's disease or known primary hyperparathyroidism

          -  previous treatment with or allergy (including hypersensitivity) to bisphosphonates

          -  recent history (past 12 months) of peptic or duodenal ulcers or oesophagitis,
             aspiration or any other abnormality of the oesophagus

          -  current therapy with prescribed calcium or vitamin D preparations (other than
             over-the-counter multivitamin preparations)

          -  current therapy with aspirin or other regularly prescribed non-steroidal
             anti-inflammatory drugs

          -  recent dental work (within the past 3 months) or poor oral hygiene (as judged in the
             opinion of the investigator)

          -  recent (within the past three months) significant steroid exposure

          -  for female subjects: pregnancy at screening, planning future pregnancies or unwilling
             to take measures to avoid pregnancy for the duration of the study

          -  where in the investigator's opinion, there is a necessity to initiate ART within the
             pre-ART study window period

          -  hepatitis B or hepatitis C co-infection

          -  any active illness (including AIDS illness) which in the opinion of the investigator
             precludes participation in the study

          -  subjects concurrently enrolled in another clinical trial of an investigational medical
             product
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patrick WG Mallon, MB BCh BAO,PhD,FRCPI</last_name>
    <role>Principal Investigator</role>
    <affiliation>University College Dublin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tara McGinty, MB, BCh, BAO</last_name>
    <email>tara.mcginty@ucd.ie</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Alan Macken, BA</last_name>
    <email>alan.macken@ucd.ie</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>7</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tara McGinty, MB, BCh, BAO</last_name>
      <email>tara.mcginty@ucd.ie</email>
    </contact>
    <contact_backup>
      <last_name>Patrick WG Mallon, MB BCh, PhD, FRCPI</last_name>
      <email>paddy.mallon@ucd.ie</email>
    </contact_backup>
    <investigator>
      <last_name>John Lambert, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerard Sheehan, MB BCh BAO, FRCPI</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <zip>9</zip>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel McConkey, MB BCh, MD,MRCPI</last_name>
      <email>smcconkey@rcsi.ie</email>
    </contact>
    <contact_backup>
      <last_name>Nora McNally, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>Ireland</country>
  </location_countries>
  <link>
    <url>http://bit.ly/SMMS_HIV</url>
    <description>HIV Molecular Research Group</description>
  </link>
  <reference>
    <citation>Cotter AG, Sabin CA, Simelane S, Macken A, Kavanagh E, Brady JJ, McCarthy G, Compston J, Mallon PW; HIV UPBEAT Study Group. Relative contribution of HIV infection, demographics and body mass index to bone mineral density. AIDS. 2014 Sep 10;28(14):2051-60. doi: 10.1097/QAD.0000000000000353.</citation>
    <PMID>25265073</PMID>
  </reference>
  <reference>
    <citation>McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV. AIDS. 2007 Nov 30;21(18):2473-82.</citation>
    <PMID>18025884</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2014</study_first_submitted>
  <study_first_submitted_qc>December 17, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>November 29, 2016</last_update_submitted>
  <last_update_submitted_qc>November 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 30, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University College Dublin</investigator_affiliation>
    <investigator_full_name>Patrick Mallon</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>human immunodeficiency virus</keyword>
  <keyword>bone diseases</keyword>
  <keyword>osteopenia</keyword>
  <keyword>osteoporosis</keyword>
  <keyword>fracture</keyword>
  <keyword>bone turnover</keyword>
  <keyword>alendronate</keyword>
  <keyword>antiretroviral</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bone Demineralization, Pathologic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin D</mesh_term>
    <mesh_term>Ergocalciferols</mesh_term>
    <mesh_term>Cholecalciferol</mesh_term>
    <mesh_term>Calcium, Dietary</mesh_term>
    <mesh_term>Alendronate</mesh_term>
    <mesh_term>Tenofovir</mesh_term>
    <mesh_term>Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

